Eur. J. Intern. Med. 2020 Jan 28
ANCA associated vasculitis.
Salvador F
Vasculitis is characterized by inflammation of the vascular wall. It reaches vessels of different sizes and locations, conditioning multisystem and co ...
Read More
Source: PubMed
Case Rep Rheumatol
Microscopic Polyangiitis with Pulmonary Fibrosis: An Often-Recognized Manifestation of the Disease.
Clifford LM, Li J, Renaud CJ, Fernando SL
Microscopic polyangiitis (MPA) can manifest with atypical features such as pulmonary fibrosis and chronic obstructive pulmonary disease (COPD), which ...
Read More
Source: PubMed
Adv Med Sci
Treatment and its side effects in ANCA-associated vasculitides - Study based on POLVAS registry data.
Biedron G, Wludarczyk A, Wawrzycka-Adamczyk K, Wójcik K, Sznajd J, Zdrojewski Z, Masiak A, Czuszynska Z, Majdan M, Jeleniewicz R, Klinger M, Jakuszko K, Rowaiye OO, Brzosko M, Brzosko I, Debska-Slizien A, Storoniak H, Tlustochowicz W, Kur-Zalewska J, Wislowska M, Madej M, Hawrot-Kawecka A, Gluszko P, Kucharz EJ, Musial J, Szczeklik W
The aim of this study is to present the treatment modalities and associated side effects in a Polish nation-wide ANCA-associated vasculitides (AAV) pa ...
Read More
Source: PubMed
Dtsch. Med. Wochenschr.
[Anti B-cell-antibody treatment for maintenance of remission in granulomatosis with polyangiitis and microscopic polyangiitis].
de Groot K, Aries PM, Haubitz M, Hellmich B, Lamprecht P, Thiel J
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most frequent primary necrotizing small vessel vasculitides. In thes ...
Read More
Source: PubMed
Pharmacol Res Perspect
Rituximab utilization for approved and off-label nononcology indications and patients' experiences with the Patient Alert Card.
Sarsour K, Beckley-Kartey S, Melega S, Odueyungbo A, Kirchner P, Khalife N, Bangs J
This study used retrospective chart review and survey data to evaluate: (1) off-label use of rituximab (MabThera®/Rituxan®) in autoimmune conditions a ...
Read More
Source: PubMed
